Case Series of Severe Neurologic Sequelae of Ebola Virus Disease during Epidemic, Sierra Leone


We describe a case series of 35 Ebola virus disease (EVD) survivors during the epidemic in West Africa who had neurologic and accompanying psychiatric sequelae. Survivors meeting neurologic criteria were invited from a cohort of 361 EVD survivors to attend a preliminary clinic. Those whose severe neurologic features were documented in the preliminary clinic were referred for specialist neurologic evaluation, ophthalmologic examination, and psychiatric assessment. Of 35 survivors with neurologic sequelae, 13 had migraine headache, 2 stroke, 2 peripheral sensory neuropathy, and 2 peripheral nerve lesions. Of brain computed tomography scans of 17 patients, 3 showed cerebral and/or cerebellar atrophy and 2 confirmed strokes. Sixteen patients required mental health follow-up; psychiatric disorders were diagnosed in 5. The 10 patients who experienced greatest disability had co-existing physical and mental health conditions. EVD survivors may have ongoing central and peripheral nervous system disorders, including previously unrecognized migraine headaches and stroke.

The 2014–2016 West Africa Ebola virus disease (EVD) epidemic resulted in an estimated 3,956 deaths and 10,168 survivors in Sierra Leone (1). The use of high-quality specialty services by Ebola survivors offers an opportunity to improve understanding of debilitating post-EVD sequelae.

Central nervous system (CNS) viral invasion by EVD had been suspected but unproven until the West Africa EVD epidemic. In this outbreak, individual case-patient reports describe clinical features of meningoencephalitis or meningitis during and after acute Ebola virus (EBOV) infection, accompanied by EBOV PCR results in nonbloodstained cerebrospinal fluid samples (CSF) (2–6). Cranial imaging of 3 encephalitic patients documented changes consistent with cerebral atrophy (3), meningoencephalitis (4), and areas of diffusion restriction suggesting ischemia (4,5). Nonhuman primate EVD models and human Marburg neuropathology found EBOV-immunoreactive glial nodules and perivascular infiltrates (7–9) and evidence of choriomeningoencephalitis (10). In addition, a novel retinal lesion in Ebola survivors that appears to follow ganglion cell axons as they exit the optic nerve has been described (11). Combined with the observation that human CSF can be EBOV PCR–positive after plasma testing shows negative results (3,4), these observations raise the possibility that infected CNS cells may have a role in persistent or recurrent neurologic disease.

Observational studies of survivors report a broad range of neuropsychiatric symptoms (12–14), including increased fatigue, diminished work capacity, and sleep disturbance (15,16). Psychosocial distress caused by bereavement, stress, and stigma and formal psychiatric diagnoses of depression, anxiety, and adjustment disorder have been reported (17–21). To define the full spectrum of characteristics and severity of neurologic and psychiatric disease, we investigated neurologic sequelae in patients with neurologic symptoms by providing specialist neurologic evaluation, psychiatric and disability assessment, and brain computed tomography (CT) imaging and retinal imaging to an EVD survivor cohort. Our additional objective was to describe psychiatric, disability, and ophthalmic outcomes for survivors with neurologic sequelae.

Author affiliations: King’s College London & King’s Health Partners, London, UK (P.J. Howlett, A.R. Walder, M. Lado, C.S. Brown); University of Sierra Leone, Freetown, Sierra Leone (D.R. Lisk, A. N’jai, G.F. Deen); University College London Great Ormond Street Institute of Child Health, London (F. Fitzgerald); Save the Children, United Kingdom and Sierra Leone, London (F. Fitzgerald); University of Nairobi, Nairobi, Kenya (S. Sevalie); 34 Military Hospital, Republic of Sierra Leone Joint Armed Forces Joint Medical Unit, Freetown (S. Sevalie, F. Sahr, F. Sesay); Lancaster University, Lancaster, UK (J.M. Read); University of Liverpool, Liverpool, UK (J.M. Read, P.J. Steptoe, N.A.V. Beare, M.G. Semple, J.T. Scott); Royal Liverpool University Hospital, Liverpool (N.A.V. Beare, R. Dwivedi); University of Manitoba, Winnipeg, Manitoba, Canada (M. Solbrig); Institute of Global Health, Walton Centre NHS Foundation Trust, Liverpool (T. Solomon)

DOI: https://doi.org/10.3201/eid2408.171367
Materials and Methods
We completed this prospective observational study during February 4–May 10, 2016. Patients eligible for inclusion were ≥12 years of age, had complete clinical records, and attended the 34 Military Hospital (34MH) Ebola Survivors Clinic, Freetown, Sierra Leone. All patients provided Ebola survivor discharge certificates as proof of identity at initial enrolment in the 34MH cohort and on attending the preliminary clinic. Furthermore, staff at the 34MH clinic provided care in the 34MH emergency treatment unit (ETU) and could certify the validity of survivors. The preliminary clinic took place at the 34MH Ebola Survivors Clinic and the specialist clinics at Connaught Hospital, Freetown, Sierra Leone.

Patients were invited to the preliminary clinic on the basis of having reported ≥1 major or ≥2 minor criteria (Table 1). These criteria were selected to maximize sensitivity for neurologic and psychiatric conditions. In addition, clinic staff invited additional patients suspected of having neurologic symptoms.

In the preliminary clinic, an intern physician, supported by trained nursing staff, obtained informed written consent to publish clinical data and images and administered an initial questionnaire. Further history and examination, including full neurologic examination, were accomplished by 2 physicians who used structured data recording forms. Patients with prominent or disabling symptoms of neurologic origin that required referral to the joint neurologic and psychiatric clinic were defined as having severe neurologic features. Patients with neurologic sequelae who did not warrant referral became a no severe neurologic features group. Laboratory tests, including lumbar puncture and brain CT, were available according to clinical need. Patients who had ≥2 psychiatric symptoms were referred for psychiatric assessment.

In the specialist clinic, full neurologic history and examination were performed individually or jointly by 2 consultant neurologists. Psychiatric assessment was performed onsite by 2 higher-level psychiatry trainees. Psychiatric assessment included Mini International Neuropsychiatric Interview (MINI-plus) and Mini Mental State Examination (MMSE; Mapi Research Trust PROVIDE, Lyon, France) and the World Health Organization Disability Assessment Schedule 2.0 (WHO-DAS 2.0; http://www.who.int/classifications/icf/whodasii/en/). The WHO-DAS 2.0 is a cross-cultural and validated tool providing a score that is compared to population percentile values (22). Although no cognitive or psychiatric assessment tools have been validated for the Sierra Leone population, the MMSE is frequently used by staff in the Connaught mental health clinic.

Table 1. Criteria used to select patients for assessment in study of severe neurologic sequelae among Ebola virus disease survivors, Sierra Leone*

<table>
<thead>
<tr>
<th>Major selection criteria</th>
<th>Minor selection criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Focal weakness</td>
<td>Headache</td>
</tr>
<tr>
<td>Tremor</td>
<td>Insomnia</td>
</tr>
<tr>
<td>Altered sensation</td>
<td>Weakness</td>
</tr>
<tr>
<td>Vision loss</td>
<td>Loss of appetite</td>
</tr>
<tr>
<td>Deafness</td>
<td>Blurred vision</td>
</tr>
<tr>
<td>Anxiety</td>
<td>Dizziness</td>
</tr>
<tr>
<td>Confusion</td>
<td></td>
</tr>
<tr>
<td>Depression</td>
<td></td>
</tr>
<tr>
<td>Psychosis</td>
<td></td>
</tr>
<tr>
<td>Inability to balance</td>
<td></td>
</tr>
<tr>
<td>Auditory disturbance</td>
<td></td>
</tr>
<tr>
<td>Tinnitus</td>
<td></td>
</tr>
<tr>
<td>Double vision</td>
<td></td>
</tr>
</tbody>
</table>

*Patients were selected for inclusion in a preliminary clinic examination if they exhibited ≥1 major or ≥2 minor criteria.

Patients underwent enhanced axial CT imaging of the brain, and scans were reviewed by a consultant neuroradiologist by using Mango software (http://ric.uthscsa.edu/mango/). All patients reviewed by specialists were invited for ophthalmologic examination, including retinal imaging. Images were reported by ophthalmologists.

Statistical Analysis
We collected data on paper forms structured for clinical use, entered it into Microsoft Excel 2011 (Microsoft, Redmond, WA, USA), and edited it for missing information. We analyzed data by using Stata version 14.0 (StataCorp LLC, College Station, TX, USA). For sample sizes ≥35, we calculated 95% CIs for proportions by using an exact binomial method. Unadjusted odds ratios were calculated for binary and ordinal variables. We used the Wilcoxon rank sum test for comparison of continuous data and the Fisher exact test for categorical data. For multivariable logistic regression of factors associated with attending or not attending the preliminary clinic, we used a predetermined model with age (linear term), sex, and presence of major or minor criteria as explanatory variables. EBOV PCR cycle threshold (Ct) (a figure inversely representative of plasma viral load, with >40 cycles used as a negative cutoff value) was not included in the regression models because different laboratories used different thresholds.

This study was reviewed in accordance with University of Liverpool human subjects review procedures and determined to be a nonresearch public health response activity. Ethics approval was confirmed in writing from the Sierra Leone Ethics and Scientific Review Committee. All data collection instruments were stored in a secured location, accessible only by study staff. Personal identifiers were removed from the database before analysis.

Results
Of 361 patients, 5 patients were excluded because clinical data were incomplete and 22 because they were <12 years of age. Of the 334 included patients, 161 (49.7%,
95% CI 44.1%–55.3%) were female and 163 (50.3%, 95% CI 44.7%–55.9%) male; sex was not recorded for 10 patients. Median patient age was 28 (IQR 23.0–37.0) years. A total of 111 (33.2%, 95% CI 28.2%–38.6%) patients were eligible for the preliminary clinic; 32 (9.6%, 95% CI 6.6%–13.3%) patients had 1 major criteria, 74 (22.2%, CI 95% 17.8%–27.0%) had ≥2 minor criteria, and 12 (3.3%, 95% CI 1.7%–5.8%) were referred by clinic staff. A total of 40 (12.0%, 95% CI 8.7%–15.9%) patients attended the clinic (Figure 1). Among the 334 patients evaluated, the most common symptoms were headache (167, 50.0%, 95% CI 44.5%–55.5%), loss of appetite (33, 9.9%, 95% CI 6.9%–13.6%), and generalized weakness (22, 6.6%, 95% CI 4.2%–9.8%) (Figure 2). Female patients were more likely to be invited to the preliminary clinic than were male patients (OR 2.01, 95% CI 1.22–3.32; p = 0.03) (online Technical Appendix Table 1, https://wwwnc.cdc.gov/EID/article/24/8/17-1367-Techapp1.pdf). In those invited to the preliminary clinic, on multivariable analysis, the presence of minor criteria was associated with nonattendance (OR 0.10, 95% CI 0.03–0.56; p = 0.005) (online Technical Appendix Table 2).

Of the 40 patients attending the preliminary clinic, 26 (65%, 95% CI 48.3%–79.3%) were female, and the median age was 32 (IQR 25–43) years. Patients were seen in the clinic a median of 430 (IQR 401–473) days after the first positive diagnostic results. At the time of preliminary clinic, 35 (87.5%, 95% CI 73.2%–95.8%) had neurologic or psychiatric symptoms (Table 2). None reported any substantial medical history of neurologic or mental health disorder. Of the 40 patients, 19 (47.5%, 95% CI 31.5%–63.9%) were defined as having severe neurologic signs and symptoms and were offered referral to the joint neurologic and psychiatric clinic, brain CT, and retinal imaging. An additional 5 patients were referred for psychiatric review only. We found no significant difference in demographic or acute EVD features between patients with and without severe neurologic features (Table 3). A greater proportion of patients with severe

---

**Figure 1.** Flowchart showing clinic referral process from initial patient cohort to preliminary clinic and then specialist clinics in study of severe neurologic sequelae among Ebola virus disease survivors, Sierra Leone. Criteria for selection for preliminary clinic assessment from the 34 Military Hospital/University of Liverpool cohort were presence of ≥1 major or ≥2 minor criteria (see Table 1) or nurse-led selection on the basis of symptoms. CT, computed tomography. *Indicates telephone number was not available or telephone was repeatedly switched off.
Neurologic symptoms were unconscious during any point in admission to the ETU, but this association was weak (OR 3.32, 95% CI 0.79–15.40; p = 0.11). Due to data sparsity, multivariable analysis was not performed.

Clinical Features

In the preliminary clinic, a new or different headache since acute EVD admission was reported by 30 (75.0%, 95% CI 58.8%–87.3%) patients; female:male ratio was 2:1. Of those with headache, 14 (46.6%, 95% CI 38.3%–65.7%) had undifferentiated headache, 13 (43.3%, 95% CI 25.5%–62.6%) migraine, and 3 (10.0%, 95% CI 2.1%–26.5%) tension-type headaches (online Technical Appendix Table 3). Five patients who had migraine headaches were prescribed oral propranolol (20 mg 1×/d), in keeping with WHO guidance on survivor care (23); 4 returned for follow-up 1 month after treatment and reported symptomatic improvement.

One male and 1 female survivor, both 42 years of age, had evidence of stroke; symptom onset occurred at the time of acute EVD. These patients had the highest disability scores (WHO Disability Assessment Schedule 2.0 scores 89.58 and 33.33, respectively) and met criteria for a mental health disorder (see Case Study 1). Given the major vessel territory distribution on CT, these strokes are suspected to be mature ischemic infarcts.

Two survivors had peripheral sensory neuropathy and 2 focal peripheral nerve lesions. Brachial plexopathy was diagnosed in a 27-year-old woman during acute EVD. Neuropathy screening of the patient for treatable causes was negative, and she was referred for physiotherapy. Asymmetric glove and stocking peripheral sensory neuropathy was diagnosed in a 35-year-old man, occurring since ETU discharge. Diabetes and major depressive disorder were diagnosed, and he was referred to the diabetes and mental health clinic. Other reported neurologic symptoms in the cohort included 3 cases of tinnitus, 2 cases of tremor, and 1 case of asymmetric lower limb atrophy with weakness of unknown etiology. Of the 19 patients who attended the specialist clinic, 12 were reviewed 1 year later, in June 2017; 10 reported improvement of symptoms, 1 reported no changes, and 1 reported a new headache. After this, case-study patient 1 died.

Psychiatric symptoms were common among 21 (52.5%, 95% CI 36.1%–68.4%) survivors describing difficulty sleeping; 12 (30.0%, 95% CI 16.5%–46.5%) described depressive symptoms and 11/40 (27.5%, 95% CI 14.6%–43.9%) anxiety symptoms (online Technical Appendix Table 4). Of 24 (60.0%, 95% CI 43.3%–75.1%) survivors referred for psychiatric review, 19 (47.5%, 95% CI 31.5–63.8%) attended the clinic. Of those, 16 (63.3%) required referral for local mental health follow-up, of whom 5 met criteria for mental disorder (2 generalized anxiety disorder; and 3 major depressive disorder). The most common reasons for mental health referral were stigma, grief, and loss of employment. Of the 19 patients who attended the psychiatric clinic, median MMSE score was 93.3% (IQR 87.7%–96.3%). No patient reported suicidal ideation.

Among 19 survivors assessed for disability, the median WHO-DAS 2.0 score was 8.3% (IQR 3.1%–13.5%) corresponding to the 69th percentile of the normative population. The 9 patients who had a disability score >10 (corresponding to scores found in <27.65% of the normative population) included all survivors affected by mental health disorders, stroke, and peripheral neuropathies for which disabilities were assessed. The most severe case of disability is described in Case Study 2.
Of 17 patients who underwent brain CT, abnormalities were shown for 7. Three scans showed evidence of cerebral or cerebellar atrophy that was atypical for patient age (Figure 3, panel A), 2 confirmed the clinical assessment of stroke (Figure 3, panel B), and 2 showed evidence of calcification, differentials of which include previous focal hemorrhage occurring ≥1 year before the scan.

Of the 40 survivors evaluated at the preliminary clinic, 12 described eye pain (30.0%, 95% CI 16.6%–46.5%) and 8 (20.0%, 95% CI 9.1%–35.6%) described partial
visual loss. Of 17 patients who attended the ophthalmology specialist clinic for examination, and wide field-scanning laser ophthalmoscope imaging, 3 (17.6%) had Ebola retinal lesions (Figure 3, panels C, D) (I). One survivor had unilateral retinal detachment, 1 intermediate uveitis, and 1 posterior subcapsular cataract suggestive of previous uveitis.

Case Studies

Case Study 1—Patient No. 25
Patient no. 25 was a previously fit and well 41-year-old male soldier who had an uncomplicated 8-day acute admission to a hospital for treatment of EVD; 3 days after discharge, he had sudden onset of left-sided weakness and dysphasia. In the neurology clinic, 545 days after his admission for acute illness, examination was consistent with a right upper motor neuron lesion. His MMSE was 26/27 and WHO-DAS 2.0 score 89.58, conforming to significant disability. He exhibited a pervasive low mood, anhedonia, feelings of worthlessness, guilt, frustration, and hopelessness regarding the future because of disability. His CT results showed extensive gliosis within the left middle cerebral artery territory, in keeping with mature infarct (Figure 3, panel C). Retinal imaging showed bilateral Ebola retinal lesions (Figure 3, panels C, D). Stroke and major depressive disorder were diagnosed. He was referred for physiotherapy, which resulted in marked improvement in symptoms, and received mental health clinic follow-up. Approximately 1 year after the initial clinic visit, the patient had an undifferentiated fever; serum from a blood sample tested EBOV PCR negative, but he died several days later.

Case Study 2—Patient No. 37
A 12-year-old girl who had a normal developmental history had a C of 27.9 at hospital admission for EVD; she improved with treatment and became serum EBOV PCR negative on days 15 and 17. On day 20, her consciousness level gradually declined and fever recurred; she then had recurrent seizures for 48 hours that were partially controlled by administration of phenytoin and diazepam. Her consciousness level gradually improved over the next 4 weeks to spontaneously alert but confused. At the preliminary clinic, 454 days after acute admission, she was blind and had substantial hearing loss and severe cognitive impairment. She was doubly incontinent and required 24-hour care for all activities of daily living. Her CT results showed disproportionate parietal and temporal lobe atrophy (Figure 3, panel C). CSF test results were EBOV negative; results of a specialist’s ophthalmology review were unremarkable. Planning for her complex care needs required multiagency and multidisciplinary coordination to find an orphanage and provide resources and training to that facility to help manage her needs. She was unable to attend the specialist neurology clinic because of the remote location of her orphanage. Follow-up visits to the orphanage from the medical, psychiatric, and therapies team found no major functional improvements.

Discussion

Previous studies have outlined the frequency of a variety of neurologic symptoms in EVD survivors (I). Our specialist case series from the 34MH survivor’s cohort confirms the presence of central and peripheral nervous system disorders and found these to be associated with a broad range of disability. The most frequent neurologic diagnosis was migraine headaches; the next most common, respectively, were stroke, peripheral sensory neuropathy, and focal peripheral nerve lesions. Most survivors had co-occurring mental health problems, the most frequent psychiatric diagnoses being major depressive disorder and generalized anxiety disorder. The most severely affected patients had symptoms of blindness, deafness, focal weakness, and cognitive dysfunction associated with disability and mental illness.

The diagnosis of migraine headache found in 13 case-patients was characterized by intermittent, throbbing headaches associated with photophobia, phonophobia, and, in some cases, vomiting. These symptoms were either new or substantially worse after acute EVD. In a small group, treatment with propranolol according to WHO guidelines (2) led to subjective improvement. To date, headaches in the EVD survivor population have not been well.
described; a small group of survivors was noted to have unilateral and throbbing headaches (19), although frequency from the 2014–2016 West Africa Ebola disease outbreak ranges 22%–68% (14,19,20,25). In the only case–control study in which 90% of survivors reported headache, a high prevalence of 75% in the control population meant this finding was not significant (16). A recent meta-analysis reported a community migraine prevalence of 5.6% (95% CI 4.6%–6.7%) in community-based studies in Africa (26). Because our preliminary clinic selection criteria required patients with headache to have ≥1 associated symptom, our headache findings and prevalence may not be representative of the survivor population. Potential mechanisms for migraine headache in EVD survivors may include autonomic dysregulation (27), changes in tryptophan-serotonin levels after infection (28), or ongoing neuroinflammation, as seen in HIV infection (29). With limited diagnostic methods, we are unable to determine specific etiologies of all neuropathy or suspected myopathy cases; however, diabetic neuropathy, entrapment neuropathy, or critical illness polyneuropathy with slow recovery are potential causes.

**Figure 3.** Representative nonenhanced computed tomography (CT) brain scans and composite scanning laser ophthalmoscope fundus images of 2 Ebola virus disease survivors attending a joint neurologic and psychiatric clinic in Sierra Leone. A) Patient no. 37, female, age 12. CT of brain shows disproportionate parietal and temporal lobe atrophy. B) Patient no. 25, male, age 42. CT of brain shows extensive gliosis within the left middle cerebral artery territory reflecting an old infarct with ex-vacuo dilatation of left lateral ventricle due to hemispheric volume loss. C) Patient no. 12, age 40. Retinal imaging shows right and left eye, with extensive bilateral peripapillary pale retinal lesions and pigmentation of larger lesions. Lesions appear to spare the fovea. Visual acuity was 20/25 (right) and 20/20 (left) (24). D) Patient no. 25, male, age 42. Retinal imaging shows right and left eye, with peripapillary pale retinal lesions. Visual acuity was 20/25 in both eyes (24).
Diagnostic imaging showed sequelae of focal or generalized atrophy or stroke in some patients. As previously reported (5,12), we found substantial cerebral atrophy in 2 patients and isolated cerebellar atrophy in 1 other survivor. One patient had a reported case of late onset encephalitis (3), and 1 patient’s imaging correlated with substantial cognitive deficit, cortical blindness, and hearing impairment (see Case Study 2). Although it is possible the atrophy was related to birth complications, nutritional deficiency, or childhood illness, the prominent parietal and temporal lobe atrophy of this adolescent case-patient resembles radiologic findings in subacute sclerosing panencephalitis, a chronic CNS infection caused by defective measles virus, raising the possibility of similar CNS mechanisms of EVD and measles or persistent CNS infection (30). Cerebral CT images of 2 stroke case-patients, whose neurologic symptom onset occurred during acute EVD, were consistent with ischemic stroke. Suspected stroke during acute EVD has been reported (31), and thromboelastography, a measurement of thrombotic tendency, done during and after acute EVD illness, suggests a prothrombotic period in the immediate aftermath of EVD (32).

In 3 (15.8%) of 19 patients in the severe neurologic features group, we observed the novel Ebola peripapillary retinal lesion, recently reported by Steptoe et al. (11), who described a similar prevalence (14.6%) among a wider survivor population. Although the most likely mechanism of CNS viral entry is from circulating infected cells, the presence of retinal peripapillary lesions, thought to represent virus spread along the retinal nerve fiber or ganglion cell axon layers, raises the possibility of CNS viral entry by neuronal spread.

The group of patients who had severe neurologic features generally had good results from adapted MMSE testing. For a patient who had a confirmed case of late-stage EVD encephalitis and initial neurocognitive impairment (3), assessment 1 year later showed good long-term recovery. This finding is encouraging and in keeping with 2 case reports of recovery from neurocognitive impairment (33). Despite onset being 1 year after acute disease and many patients having been initially referred to counselors, 5 of 19 patients met criteria for psychiatric disorder, all 19 had concurrent physical symptoms, and 16 required mental health follow-up. As previously reported, survivors cited stigma, grief, and loss of employment as major stressors impeding recovery (17,34).

A recent case–control study found survivors had major limitations of vision, cognition, affect, and, most markedly, mobility (35). In our study, we found 10 participants who reported high levels of disability and also had physical symptoms and co-occurring mental health issues. This clustering of physical and psychiatric sequelae and disability suggests a subset of patients most affected after acute EVD and with the greatest care needs. In the small number of self-selecting case-patients on whom we followed up 18 months after the first neurologic/psychiatric clinic, patients generally reported symptomatic improvement; however, improvement was not uniform. One case-patient subsequently died (patient no. 25; see Case Study 1) and another remains dependent for all activities of daily living (patient no. 37; see Case Study 2).

Our study observed no association between severe neurologic conditions and admission CT. To the contrary, among the 2 patients who had both prolonged periods of unconsciousness and cerebral atrophy on CT (patients no. 2 and 16), the neurologic episodes occurred late in the acute disease period, not at the time of peak viral load. Similarly, 2 case reports describe a prolonged meningoencephalitic stage of disease or meningoencephalitis occurring months after recovery (4,5). Of note, we found no cases of CNS infection recurrence. Unconsciousness during acute admission was more common among those who had severe neurologic symptoms on follow-up, although not to a significant degree, possibly caused by limited sample size (OR 3.32, CI 0.79–15.4; p = 0.11). Our preliminary group was selected on the basis of existing neurologic symptoms, which precludes a conclusion of causation and generalization to the wider EVD survivor population.

A major limitation of our case series is that we cannot firmly determine causation between our findings and the diagnosis of EVD beyond the temporal association. Furthermore, in keeping with other observational studies, a lack of reliable countrywide denominator data on conditions such as headache or stroke means we cannot assess the representativeness of our results. Validating our findings would require a large case–control study, in which our data could be used as a basis for study design. Retrospectively asking about acute symptoms incurs the possibility of recall bias; however, as acute records of the EBV outbreak clinics are sparse and linkage-challenging, this represented the most viable option. Despite our multiple attempts, the outcomes of 71/111 patients who were invited to but did not attend the preliminary clinic remain unknown. Although our analysis shows those with minor selection criteria were among those less likely to attend (p = 0.005), it is still possible we underrepresented patients who had more disabling conditions and were unable to access the service, as exemplified by the patient in Case Study 2. Further research should focus on a complete characterization of pathways of sequelae and persistent infection (36).

Our case series, supported by brain CT imaging, confirms there are long-term neurologic sequelae in EVD survivors and a substantial proportion of these patients have ongoing mental health problems and disability. Often, these issues cluster together, and services should therefore seek out and support patients with a high burden of illness. If we wish to expand specialist services to the remaining EVD survivors and broader population, the only credible and sustainable option is to greatly increase support for in-country specialist training of doctors.
Acknowledgments

We thank the study participants, the Sierra Leone Association of Ebola Survivors; the staff at 34 Military Hospital; the Main Outpatients Department, Radiology Department, and administration, Connaught Hospital; and the Sierra Leone Research Ethics Committee for their guidance.

This research was supported by the Wellcome Enhancing Research Activity in Epidemic Situations Grants (reference: 107779/Z/15/B) and the National Institute for Health Research (NIHR) Health Protection Research Unit in Emerging and Zoonotic Infections at University of Liverpool in partnership with Public Health England, in collaboration with Liverpool School of Tropical Medicine. Follow-up neurological assessments were completed as part of the Ministry of Health and Sanitation’s Comprehensive Package for Ebola Survivors program, funded from USAID through JSI Research & Training Institute, Inc. The funding source had no direct involvement in investigational design, conduct, data collection, data analysis, data interpretation, and writing of the report. The corresponding author had full access to the study data. All authors share the responsibility for the submission for publication. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, the Department of Health, or Public Health England.

About the Author

Dr. Howlett works with the King’s Sierra Leone Partnership in Connaught Hospital, Sierra Leone. His areas of interest are respiratory medicine, tuberculosis, and strengthening health systems.

References


HIV is a virus spread through certain body fluids that attacks the body’s immune system—specifically the CD4 cells, often called T cells. These special cells help the immune system fight off infections. Untreated, HIV reduces the number of CD4 cells (T cells) in the body. Over time, HIV can destroy so many of these cells that the body can’t fight off infections and disease. This damage to the immune system makes it harder and harder for the body to fight off infections and some other diseases. Opportunistic infections or cancers take advantage of a very weak immune system and signal that the person has AIDS.

http://wwwnc.cdc.gov/eid/page/world-aids

Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 8, August 2018
Case Series of Severe Neurologic Sequelae of Ebola Virus Disease during Epidemic, Sierra Leone

Technical Appendix

Technical Appendix Table 1. Univariate analysis of major or minor inclusion criteria, age, and cohort clinic symptoms according to sex in cohort of Ebola virus disease survivors (n = 334)* † ‡ §

<table>
<thead>
<tr>
<th>Category</th>
<th>Invited to preliminary clinic</th>
<th>Not invited to preliminary clinic</th>
<th>Crude odds ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fit neurology criteria for invitation*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All</td>
<td>111</td>
<td>223</td>
<td>NA</td>
</tr>
<tr>
<td>M</td>
<td>42 (39)</td>
<td>123 (56)</td>
<td>1</td>
</tr>
<tr>
<td>F</td>
<td>66 (61)</td>
<td>96 (44)</td>
<td>2.01 (1.22 – 3.32)</td>
</tr>
<tr>
<td>Fit major criteria</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All</td>
<td>32</td>
<td>299</td>
<td>NA</td>
</tr>
<tr>
<td>M</td>
<td>8 (25)</td>
<td>155 (52)</td>
<td>1</td>
</tr>
<tr>
<td>F</td>
<td>23 (75)</td>
<td>138 (48)</td>
<td>3.25 (1.34 – 8.65)</td>
</tr>
<tr>
<td>Fit minor criteria</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All</td>
<td>74</td>
<td>260</td>
<td>NA</td>
</tr>
<tr>
<td>M</td>
<td>29 (39)</td>
<td>134 (52)</td>
<td>1</td>
</tr>
<tr>
<td>F</td>
<td>43 (58)</td>
<td>118 (46)</td>
<td>1.60 (0.96 – 3.00)</td>
</tr>
<tr>
<td>Invited by clinic staff</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All</td>
<td>12</td>
<td>322</td>
<td>NA</td>
</tr>
<tr>
<td>M</td>
<td>6 (50)</td>
<td>0 (0)</td>
<td>1</td>
</tr>
<tr>
<td>F</td>
<td>6 (50)</td>
<td>0 (0)</td>
<td>1.02 (0.27 – 3.90)</td>
</tr>
<tr>
<td>Age (years, IQR)†</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All</td>
<td>29 (22–38)</td>
<td>28 (23–36)</td>
<td>0.007 per +1 y (0.016–0.022)</td>
</tr>
<tr>
<td>M</td>
<td>29 (22–38)</td>
<td>27 (24–35)</td>
<td>NA</td>
</tr>
<tr>
<td>F</td>
<td>27 (23–35)</td>
<td>29 (22–37)</td>
<td>NA</td>
</tr>
<tr>
<td>Major criteria</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Focal Weakness</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All</td>
<td>7</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>M</td>
<td>2 (29)</td>
<td>NA</td>
<td>1</td>
</tr>
<tr>
<td>F</td>
<td>5 (71)</td>
<td>NA</td>
<td>2.58 (0.41–27.4)</td>
</tr>
<tr>
<td>Tremor</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All</td>
<td>5</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>M</td>
<td>1 (20)</td>
<td>NA</td>
<td>1</td>
</tr>
<tr>
<td>F</td>
<td>4 (80)</td>
<td>NA</td>
<td>4.11 (0.40–204.46)</td>
</tr>
<tr>
<td>Altered Sensation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All</td>
<td>1</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>M</td>
<td>0</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>F</td>
<td>1 (100)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Visual loss</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All</td>
<td>5</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>M</td>
<td>0</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>F</td>
<td>5 (100)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Deafness</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All</td>
<td>3</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>M</td>
<td>1 (33)</td>
<td>NA</td>
<td>1</td>
</tr>
<tr>
<td>F</td>
<td>2 (66)</td>
<td>NA</td>
<td>2.04 (0.10–120.94)</td>
</tr>
<tr>
<td>Anxiety</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All</td>
<td>3</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>M</td>
<td>1 (33)</td>
<td>NA</td>
<td>1</td>
</tr>
<tr>
<td>F</td>
<td>2 (66)</td>
<td>NA</td>
<td>2.04 (0.10–120.9)</td>
</tr>
<tr>
<td>Confusion</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All</td>
<td>0</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Category</td>
<td>Invited to preliminary clinic</td>
<td>Not invited to preliminary clinic</td>
<td>Crude odds ratio (95% CI)</td>
</tr>
<tr>
<td>----------------------------------</td>
<td>--------------------------------</td>
<td>----------------------------------</td>
<td>---------------------------</td>
</tr>
<tr>
<td>Fit neurology criteria for invitation*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>M</td>
<td>0</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>F</td>
<td>1 (100)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Depression</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>M</td>
<td>4</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>F</td>
<td>2 (50)</td>
<td>NA</td>
<td>1</td>
</tr>
<tr>
<td>Psychosis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>M</td>
<td>1 (100)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>F</td>
<td>2 (50)</td>
<td>NA</td>
<td>1.01 (0.073–14.12)</td>
</tr>
<tr>
<td>Inability to balance</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>M</td>
<td>1</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>F</td>
<td>1 (100)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Double vision</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>M</td>
<td>1</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>F</td>
<td>0</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Tinnitus</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>M</td>
<td>1</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>F</td>
<td>1 (100)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Minor criteria‡</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All</td>
<td>74</td>
<td>93</td>
<td>NA</td>
</tr>
<tr>
<td>M</td>
<td>24 (32)</td>
<td>49 (45)</td>
<td>1</td>
</tr>
<tr>
<td>F</td>
<td>50 (68)</td>
<td>42 (53)</td>
<td>2.23 (1.39–3.56)</td>
</tr>
<tr>
<td>Insomnia</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All</td>
<td>13</td>
<td>4</td>
<td>NA</td>
</tr>
<tr>
<td>M</td>
<td>6 (46)</td>
<td>2 (50)</td>
<td>1</td>
</tr>
<tr>
<td>F</td>
<td>7 (54)</td>
<td>2 (50)</td>
<td>1.01 (0.32–3.18)</td>
</tr>
<tr>
<td>Weakness</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All</td>
<td>15</td>
<td>7</td>
<td>NA</td>
</tr>
<tr>
<td>M</td>
<td>6 (40)</td>
<td>5 (71)</td>
<td>1</td>
</tr>
<tr>
<td>F</td>
<td>9 (60)</td>
<td>2 (29)</td>
<td>0.91 (0.33–2.45)</td>
</tr>
<tr>
<td>Loss of appetite</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All</td>
<td>25</td>
<td>8</td>
<td>NA</td>
</tr>
<tr>
<td>M</td>
<td>12 (48)</td>
<td>7 (88)</td>
<td>1</td>
</tr>
<tr>
<td>F</td>
<td>13 (52)</td>
<td>1 (13)</td>
<td>0.61 (0.26–1.38)</td>
</tr>
<tr>
<td>Dizziness</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All</td>
<td>21</td>
<td>1</td>
<td>NA</td>
</tr>
<tr>
<td>M</td>
<td>6 (29)</td>
<td>0 (0)</td>
<td>1</td>
</tr>
<tr>
<td>F</td>
<td>15 (71)</td>
<td>1 (100)</td>
<td>2.88 (1.03–9.23)</td>
</tr>
</tbody>
</table>

*Values are no. (%) patients except as indicated.
†Sex not available for 7 patients (n = 327). F, female; M, male; NA, not applicable.
‡Age not available for 22 patients (n = 312 patients).
§Symptoms not available for additional 3 patients (n = 331).
Technical Appendix Table 2. Crude odds ratio and multivariable adjusted regression analysis comparing of patients invited and who did attend the preliminary clinic and those invited but did not attend the preliminary clinic*

<table>
<thead>
<tr>
<th>Variable Total</th>
<th>Invited and attended (%)</th>
<th>Invited did not attend (%)</th>
<th>Crude OR (95% CI)</th>
<th>Adjusted OR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex (n = 108*)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>M</td>
<td>42 (39)</td>
<td>14 (33)</td>
<td>28 (66)</td>
<td>1.30 (0.53–3.19)</td>
</tr>
<tr>
<td>F</td>
<td>66 (61)</td>
<td>26 (39)</td>
<td>40 (61)</td>
<td></td>
</tr>
<tr>
<td>Age, years (n = 111)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median (IQR)</td>
<td>(22–38)</td>
<td>(25–43)</td>
<td>(21–35)</td>
<td>0.009 (0.0018–0.018) per + 1 y</td>
</tr>
<tr>
<td>Fitted major criteria†</td>
<td>26</td>
<td>13 (35)</td>
<td>13 (27)</td>
<td>1.48 (0.57–3.77)</td>
</tr>
<tr>
<td>Fitted minor criteria†</td>
<td>104</td>
<td>18 (49)</td>
<td>56 (79)</td>
<td>0.25 (0.10–0.65)</td>
</tr>
</tbody>
</table>

*Female/male sex not available for 3 cases; NA, not applicable.
†Data available for 108/111 patients invited to the preliminary clinic; 3 patients invited to the preliminary clinic by clinic had attended the 34MH clinic after data collection of initial review of notes had been made.

Technical Appendix Table 3. Demographics, acute presentation, cycle threshold values, neurologic features, mini-mental state examination (MMSE), WHO Disability Score 2.0 (WHODAS), CT brain findings, diagnosis and management and outcome of 35 patients with neurologic and psychiatric diagnoses, and 1 further ophthalmology diagnosis attending preliminary and specialists neurology and psychiatric clinics*

<table>
<thead>
<tr>
<th>Pt no</th>
<th>Acute disease features (Length of stay/days)</th>
<th>Neurologic features at review in clinic - time since acute disease/days, symptoms and examination findings, MMSE and WHO-DAS 2.0 score, selected serum, cerebrospinal fluid radiographic, ECG and retinal investigations</th>
<th>Neurologic/psychiatric diagnosis</th>
<th>Management and outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 (M/47)</td>
<td>Fever, chest pain, arthralgia/myalgia, intense fatigue, headache, shortness of breath, altered consciousness, nausea, vomiting, diarrhea, unconscious (11 d), C, value – 30.3</td>
<td>(413 d) Intermittent all over headache, lasting up to one week, occurring approximately every 2 weeks. Resolved on review in specialist clinic. Visual disturbance – intermittent scotoma. MMSE 30/30. WHO-DAS 0. CT Brain - Relative cerebellar volume loss. Retinal imaging - Left retinal detachment. Right normal.</td>
<td>Resolved migraine headache, arthralgia, left retinal detachment.</td>
<td>Simple analgesia. Review at 1 y – ongoing symptoms</td>
</tr>
<tr>
<td>3 (M/33)</td>
<td>Fever, sore throat, chest pain, arthralgia/myalgia, intense fatigue, headache, altered consciousness, abdominal pain, conjunctivitis, rash, unconscious (23 d)</td>
<td>(409 d) Band-like headache, sometimes so severe it makes him feel confused. Lasts between 1 week to 1 d. Associated with scotoma. Retinal imaging - Normal bilaterally.</td>
<td>Migraine headache</td>
<td>DNA specialist clinic</td>
</tr>
<tr>
<td>4 (F/54)</td>
<td>Fever, sore throat, runny nose, chest pain, joint pain, intense fatigue, headache, shortness of breath (26 d)</td>
<td>(537 d) Intermittent dizziness, altered taste in mouth, feels like burning when eats. Joint pains. All over headache with scotoma. Visual hallucinations/flashbacks, feeling of anxiety, restlessness and irritability. On</td>
<td>Psychosocial issues. Symmetric large joint polyarthritis Undifferentiated headache</td>
<td>Referred to psychiatry for assessment but did not attend</td>
</tr>
<tr>
<td>Pt no (Sex/Age)</td>
<td>Acute disease features (Length of stay/days) (Zaire Ebola virus PCR result/Ct value)</td>
<td>Neurologic features at review in clinic - time since acute disease/days, symptoms and examination findings, MMSE and WHO-DAS 2.0 score, selected serum, cerebrospinal fluid radiographic, ECG and retinal investigations</td>
<td>Neurologic/psychiatric diagnosis</td>
<td>Management and outcome</td>
</tr>
<tr>
<td>----------------</td>
<td>---------------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------------------------------------------------------</td>
<td>---------------------------------</td>
<td>------------------------</td>
</tr>
<tr>
<td>6 (F/18)</td>
<td>Fever, cough, sore throat, runny nose, chest pain, arthralgia/myalgia, intense fatigue, <strong>headache</strong>, shortness of breath, <strong>altered consciousness</strong>, abdominal pain, nausea, vomiting, diarrhea, conjunctivitis, rash, skin ulcer (8 d)</td>
<td>(413 d) New generalized headache no associated symptoms. Joint pains and cough</td>
<td>Undifferentiated headache, arthralgia</td>
<td>Referred back to general survivor's clinic</td>
</tr>
<tr>
<td>7 (F/21)</td>
<td>Fever, cough, sore throat, runny nose, ear ache, chest pain, arthralgia/myalgia, <strong>headache</strong>, shortness of breath, <strong>altered consciousness</strong>, nausea, vomiting, diarrhea, conjunctivitis, rash, <strong>unconscious</strong> (18 d), C; value – 19.4</td>
<td>(480 d) Band-like headache, present most of the time (daily). Associated scotoma. Vaginal candidiasis and itchy skin. Hallucinations and feeling of anxiety. Low mood, poor sleep, anhedonia, irritability, angry outbursts, isolated, stigmatised by community. MMSE 28/29. WHO-DAS 10.42</td>
<td>Tension-type headache, major depressive disorder, vaginal candidiasis</td>
<td>Local mental health follow-up, diprobase for skin</td>
</tr>
<tr>
<td>8 (F/29)</td>
<td>Fever, hemoptysis, sore throat, ear ache, arthralgia/myalgia, intense fatigue, <strong>headache</strong>, shortness of breath, <strong>altered consciousness</strong>, <strong>seizures</strong>, abdominal pain, nausea, vomiting, diarrhea, conjunctivitis, rash (14 d), C; value – 23.4</td>
<td>(398 d) Generalized headache with no associated symptoms. Intermittent visual</td>
<td>Undifferentiated headache</td>
<td>Referred back to general survivor's clinic</td>
</tr>
<tr>
<td>9 (F/26)</td>
<td>Fever, hemoptysis, chest pain, joint pains, <strong>headache</strong>, shortness of breath, <strong>altered consciousness</strong>, <strong>seizures</strong>, abdominal pain, nausea, vomiting, diarrhea, conjunctivitis, rash (14 d), C; value – 23.4</td>
<td>(394 d) Headache, frontal, nightly, little improvement with analgesia. Associated with blurred/altered vision. Bony and joint pains. Hallucinations, feelings of anxiety and restlessness</td>
<td><strong>Migraine headache</strong></td>
<td>Referred to MH for assessment but did not attend. Review at 1 y – improvement in symptoms</td>
</tr>
<tr>
<td>10 (F/27)</td>
<td>Fever, hemoptysis, <strong>headache</strong>, <strong>altered consciousness</strong>, <strong>seizures</strong>, nausea, vomiting, diarrhea, <strong>unconscious</strong> (2 d) (44 d)</td>
<td>(408 d) New right arm weakness since discharge. On examination, lower motor neuron weakness (3/5) and sensory impairment right upper limb, MMSE 18/21. WHO-DAS 14.58. Brain CT – Normal study. Retinal imaging - Normal bilaterally</td>
<td><strong>Right brachial plexus neuropathy</strong></td>
<td>Physiotherapy, analgesia. Review at 1 y - significant improvement in weakness</td>
</tr>
<tr>
<td>11 (F/42)</td>
<td>Fever, intense fatigue, <strong>headache</strong>, <strong>altered consciousness</strong>, nausea, vomiting, conjunctivitis, <strong>unconscious</strong> (33 d), C; value – 22.1</td>
<td>(398 d) Right sided weakness occurred during admission now improved but still cannot write (R handed). Pervasive low mood as unable to carry out activities of daily living, anhedonia, feeling of worthlessness, tearful in clinic. On examination, right VII weakness, right upper limb: 4/5</td>
<td><strong>Right striatocapsular infarct, Generalized Anxiety Disorder</strong></td>
<td>Physiotherapy, MH follow up</td>
</tr>
<tr>
<td>Pt no (Sex/Age)</td>
<td>Acute disease features (Length of stay/days) (Zaire Ebola virus PCR result/Ct value)</td>
<td>Neurologic features at review in clinic - time since acute disease/days, symptoms and examination findings, MMSE and WHO-DAS 2.0 score, selected serum, cerebrospinal fluid radiographic, ECG and retinal investigations</td>
<td>Neurologic/psychiatric diagnosis</td>
<td>Management and outcome</td>
</tr>
<tr>
<td>----------------</td>
<td>----------------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>13 (F/58)</td>
<td>Fever, cough, runny nose, ear ache, chest pain, arthralgia/myalgia, <strong>headache</strong>, shortness of breath, <strong>altered consciousness</strong>, abdominal pain, nausea, vomiting, diarhhea, conjunctivitis (31 d)</td>
<td>(497 d) All over headache associated with blurred/alterned vision and eye pains. Reflux symptoms. Generalized weakness and subjective changes in thinking</td>
<td>Undifferentiated headache</td>
<td>Referred back to general survivor’s clinic</td>
</tr>
<tr>
<td>14 (M/38)</td>
<td>Fever, hemoptysis, sore throat, chest pain, arthralgia/myalgia, <strong>headache</strong>, shortness of breath, seizures, abdominal pain, nausea, diarrhea, unconsciousness (18 d) C; value – 24.1</td>
<td>(441 d) Intermittent all over headaches associated with fever, eye pains and photophobia</td>
<td>Possible anterior uveitis</td>
<td>Undifferentiated headache</td>
</tr>
<tr>
<td>15 (F/49)</td>
<td>Fever, cough with sputum, chest pain, arthralgia/myalgia, intense fatigue, <strong>altered consciousness</strong>, abdominal pain, nausea, vomiting, <strong>unconsciousness</strong> (11 d)</td>
<td>(452 d) Headache 2–3 times weekly, constant, band-like. Associated problems with distant vision in left eye. Improves with rest and analgesia</td>
<td>Tension-type headache</td>
<td>Referred back to general survivor’s clinic</td>
</tr>
<tr>
<td>16 (F/31)</td>
<td>Fever, sore throat, arthralgia/myalgia, <strong>headache</strong>, <strong>altered consciousness</strong>, abdominal pain, nausea, vomiting, diarhhea, unconscious –2 weeks (19 d) C; value – 23.5</td>
<td>(435 d) All over headache, aching, lasting 3–5 h, worse on carrying loads and associated with photophobia and dizziness. MMSE 28/27. WHO-DAS 12.50. Brain CT - Cerebral and cerebellar volume loss. Retinal imaging - Normal fundus</td>
<td>Migraine headache</td>
<td>Propranolol 20 mg daily with improved symptoms (unable to quantify)</td>
</tr>
<tr>
<td>17 (F/51)</td>
<td>Fever, hemoptysis, sore throat, runny nose, ear ache, chest pain, arthralgia/myalgia,</td>
<td>(402 d) Headache, no associated symptoms. Altered sensations in feet. Difficulties with doing up buttons. On</td>
<td>Undifferentiated headache Peripheral sensory neuropathy</td>
<td>Referred back to general survivor’s clinic</td>
</tr>
<tr>
<td>Pt no (Sex/Age)</td>
<td>Acute disease features (Length of stay/days) (Zaire Ebola virus PCR result/Ct value)</td>
<td>Neurologic features at review in clinic - time since acute disease/days, symptoms and examination findings, MMSE and WHO-DAS 2.0 score, selected serum, cerebrospinal fluid radiographic, ECG and retinal investigations</td>
<td>Neurologic/pyschiatric diagnosis</td>
<td>Management and outcome</td>
</tr>
<tr>
<td>-----------------</td>
<td>-------------------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------------------------------------------------------</td>
<td>-------------------------------</td>
<td>------------------------</td>
</tr>
<tr>
<td>18 (F/32)</td>
<td>Fever, hemoptysis, ear ache, chest pain, arthralgia/myalgia, headache, abdominal pain, nausea, diarrhea, conjunctivitis, unconsciousness (30 d); C value – 28.2</td>
<td>(448 d) All over headache triggered when thinks of family passing away. Feels like a pressure in head and vertigo. Reported visual hallucinations, irritability and anxiety. Joint pains. On examination, fixed boutonieres deformity 3rd and 4th MCP joints. Short of breath on exertion. MMSE 24/26. WHO-DAS 2.08. CXR/ECG normal. Retinal imaging - Right normal fundus</td>
<td>Undifferentiated headache, arthralgia</td>
<td>Local MH follow-up</td>
</tr>
<tr>
<td>20 (M/38)</td>
<td>Fever, hemoptysis, sore throat, runny nose, ear ache, chest pain, arthralgia/myalgia, headache, abdominal pain, nausea, diarrhea, conjunctivitis, bleeding (miscarriage) (28 d); C value – 30.4</td>
<td>(395 d) Initial presentation with right sided headache associated with photophobia and scotoma. Resolved on review in specialist clinic. MMSE 20/22. WHO-DAS 4.17. RBG 5.0 mmol/L. Brain CT – Normal study. Retinal imaging - Normal bilaterally</td>
<td>Resolved migraine headache, arthralgia</td>
<td>Analgesia. Review at 1 y – new onset headache with cluster-type features</td>
</tr>
<tr>
<td>22 (F/21)</td>
<td>Fever, hemoptysis, arthralgia/myalgia, headache, shortness of breath, nausea, vomiting, unconscious (27 d)</td>
<td>(376 d) Severe, pounding headaches, vertex to occiput with intermittent blurring of vision and dizziness. Photophobia and phonophobia. Occur monthly, lasting 5–7 d. Tinnitus. Subjectively mentally slow for 1 mo post discharge</td>
<td>Migraine headache</td>
<td>Propranolol 20 mg daily. Headache improved 8/10 to 4/10. Review at 1 y – no further migraine symptoms</td>
</tr>
<tr>
<td>Pt no (Sex/Age)</td>
<td>Acute disease features (Length of stay/days)</td>
<td>Neurologic features at review in clinic - time since acute disease/days, symptoms and examination findings, MMSE and WHO-DAS 2.0 score, selected serum, cerebrospinal fluid radiographic, ECG and retinal investigations</td>
<td>Neurologic/psychiatric diagnosis</td>
<td>Management and outcome</td>
</tr>
<tr>
<td>----------------</td>
<td>---------------------------------------------</td>
<td>-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>---------------------------------</td>
<td>------------------------</td>
</tr>
<tr>
<td>23 (M/46)</td>
<td>Fever, cough with sputum, sore throat, runny nose, ear ache, chest pain, arthralgia/myalgia, intense fatigue, <strong>headache</strong>, shortness of breath, <strong>altered consciousness</strong>, abdominal pain, nausea, vomiting, conjunctivitis, rash (24 d), C(_2) value – 34.7</td>
<td>(424 d) All over headache associated with dizziness. Bilateral lower limb tremor. On examination, bilaterally lower limb tremor worse on movement. Brain CT - Focus calcification at right globus pallidus. Retinal imaging - Left 3 choriotetinal pigmented lesions. Right choriotetinal lesion emanating from the optic disc, and peripheral pigmented lesion with pigmentation of the retinal vasculature</td>
<td>Essential tremor, undifferentiated headache</td>
<td>DNA specialist clinic</td>
</tr>
<tr>
<td>24 (F/43)</td>
<td>Fever, cough, runny nose, chest pain, arthralgia/myalgia, <strong>headache</strong>, shortness of breath, <strong>altered consciousness</strong>, nausea, vomiting, rash (9 d), C(_2) value – 20.7</td>
<td>(404 d) Headaches since discharge. 2–3x weekly lasting few hours up to 2 d. Frontal, not pbounding more like an ache, photophobia and phonophobia. Occasional vomiting, helped by paracetamol. Previous mild headaches. MMSE 30/30. Brain CT - Normal study. Retinal imaging - Intermediate uveitis left eye. Right normal fundus</td>
<td>Migraine headache</td>
<td>Propranolol 20 mg daily, initially 10/10 headache pain now better (not able to quantify). Review at 1 y – decreased frequency of headaches, now occasional</td>
</tr>
<tr>
<td>25 (M/42)</td>
<td>Fever, runny nose, ear ache, chest pains, arthralgia/myalgia, intense fatigue, <strong>headache</strong>, shortness of breath, <strong>altered consciousness</strong>, abdominal pain, nausea, vomiting, diarrhea, conjunctivitis (8 d)</td>
<td>(545 d) Sudden onset weakness of left side occurring 4 d post discharge. Speech and comprehension difficulties. Pervasive low mood, anhedonia, feelings of worthlessness, guilt, frustration and hopelessness. Left hemiplegia, hemiasthenia, left homonymous hemianopia. MMSE 26/27. WHO-DAS 89.58. Brain CT - Mature right MCA infarct. Retinal imaging - Bilateral Ebola retinal lesion</td>
<td>Extensive right MCA infarct, major depressive disorder</td>
<td>Physiotherapy, MH follow up. Review at 1 y – improvement in symptoms. Patient subsequently died</td>
</tr>
<tr>
<td>26 (F/25)</td>
<td>Fever, hemoptysis, sore throat, runny nose, ear ache, chest pain, arthralgia/myalgia, intense fatigue, <strong>headache</strong>, shortness of breath, abdominal pain, nausea, vomiting, conjunctivitis, rash, <strong>unconscious</strong> (31 d)</td>
<td>(272 d) Pain and weakness right upper limb. Right upper limb; atrophy and 4/5 power in ulnar nerve distribution, no sensory impairment. Brain CT - Small focal calcification left mesial temporal lobe</td>
<td>Ulnar nerve palsy</td>
<td>DNA specialist clinic</td>
</tr>
<tr>
<td>27 (M/25)</td>
<td>Fever, cough with sputum, sore throat, runny nose, arthralgia/myalgia, intense fatigue, <strong>headache</strong>, <strong>altered consciousness</strong>, abdominal pain, nausea,</td>
<td>(422 d) Right sided headache with photophobia and phonophobia. Left thigh wasting and 4/5 power left HF/KF. MMSE 29/29. WHO-DAS 8.25. RBG 5.0 mm/L.</td>
<td>Migraine headache, arthralgia</td>
<td>Analgesia, MH follow up. Review at 1 y – decreased frequency of headaches, now occasional</td>
</tr>
<tr>
<td>Pt no (Sex/Age)</td>
<td>Acute disease features (Length of stay/days)</td>
<td>Neurologic features at review in clinic - time since acute disease/days, symptoms and examination findings, MMSE and WHO-DAS 2.0 score, selected serum, cerebrospinal fluid radiographic, ECG and retinal investigations</td>
<td>Neurologic/psychiatric diagnosis</td>
<td>Management and outcome</td>
</tr>
<tr>
<td>---------------</td>
<td>---------------------------------------------</td>
<td>---------------------------------------------------------------------------------------------------</td>
<td>----------------------------------</td>
<td>-------------------------</td>
</tr>
<tr>
<td>28 (F/21)</td>
<td>Fever, runny nose, chest pain, arthralgia/myalgia, headache, altered consciousness, abdominal pain, nausea, vomiting, diarrhea, skin rash, unconscious - 20 d (14 d)</td>
<td>(455 d) Approximately monthly, frontal, pounding headache, lasting a few hours. Improving symptoms. Currently pregnant 24/42. MMSE 19/26. WHO-DAS 0. Retinal imaging - Bilateral Ebola retinal lesion. Left WWP. Right normal fundus, small posterior subcapsular cataract</td>
<td>Tension-type headache</td>
<td>Analgesia. Review at 1 y - decreased frequency of headaches, now occasional. Lost pregnancy with fever/rash</td>
</tr>
<tr>
<td>29 (F/61)</td>
<td>Fever, cough with sputum, sore throat, runny nose, chest pain, intense fatigue, headache, altered consciousness, conjunctivitis, unconsciousness (12 d), C4 value – 21.0</td>
<td>(403 d) Constant headache, bank-like with associated eye pain and photophobia. Generalized joint pains with longstanding right knee pain. Generalized weakness. Difficulty sleeping and depression. MMSE 28/30. WHO-DAS 12.5. Retinal imaging - Bilateral subcapsular cataract with several pigmented peripheral lesions</td>
<td>Migraine headache, bilateral cataract, arthralgia</td>
<td>Local MH follow up</td>
</tr>
<tr>
<td>30 (F/19)</td>
<td>Fever, cough, sore throat, chest pain, arthralgia/myalgia, intense fatigue, headache, altered consciousness, abdominal pain, nausea, vomiting, rash. 21 d</td>
<td>(502 d) Bilateral red eyes and eye pain with associated constant headache and intermittent fevers. Bilateral knee pains.</td>
<td>Anterior uveitis, undifferentiated headache</td>
<td>Urgent referral to local ophthalmology clinic</td>
</tr>
<tr>
<td>32 (F/43)</td>
<td>Fever, cough, sore throat, runny nose, wheeze, chest pain, arthralgia/myalgia, headache, shortness of breath, altered consciousness, abdominal pain, nausea, vomiting, diarrhea, conjunctivitis, rash (28 d)</td>
<td>(471 d) Cloudy vision, intermittent headache with no added symptoms. Symmetric pains in joints with stiff fingers. On examination, fixed boutonniere deformity 3rd and 4th MCP joints. Bilateral cataracts</td>
<td>Undifferentiated headache, arthralgia</td>
<td>Referred to local ophthalmology clinic</td>
</tr>
<tr>
<td>33 (F/41)</td>
<td>Fever, sore throat, chest pain, arthralgia/myalgia, headache, shortness of breath, altered consciousness, nausea,</td>
<td>(497 d) Right sided headache, sharp but pounding with noises. Associated photophobia and blurred vision. MMSE 15/21. WHO-DAS 2.08. Brain CT – Normal study.</td>
<td>Migraine headache, arthralgia, anxiety</td>
<td>MH follow up, simple analgesia. Review at 1 y - decreased frequency of</td>
</tr>
<tr>
<td>Pt no (Sex/Age)</td>
<td>Acute disease features (Length of stay/days)</td>
<td>Neurologic features at review in clinic - time since acute disease/days, symptoms and examination findings, MMSE and WHO-DAS 2.0 score, selected serum, cerebrospinal fluid radiographic, ECG and retinal investigations</td>
<td>Neurologic/psychiatric diagnosis</td>
<td>Management and outcome</td>
</tr>
<tr>
<td>----------------</td>
<td>---------------------------------------------</td>
<td>--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>---------------------------------</td>
<td>------------------------</td>
</tr>
<tr>
<td>34 (F/25)</td>
<td>Fever, sore throat, chest pain, arthralgia/myalgia, intense fatigue, <strong>headache</strong>, vomiting, nausea, diarrhea (18 d)</td>
<td>(398 d) All over headache with no associated symptoms. Reduced visual acuity right eye</td>
<td>Undifferentiated headache</td>
<td>Referred to general survivor's clinic</td>
</tr>
<tr>
<td>35 (M/35)</td>
<td>Fever, sore throat, runny nose, wheeze, chest pain, arthralgia/myalgia, intense fatigue, <strong>headache</strong>, altered consciousness, seizures, nausea, vomiting, diarrhea, conjunctivitis, rash (28 d)</td>
<td>(515 d) Left sided pounding headache 4 mo after discharge, associated photophobia/phonophobia, occurring approximately monthly. Burning in feet, started 1 y after discharge. Pervasive low mood, difficulty sleeping. On examination, asymmetric glove and stocking peripheral neuropathy, light touch and pinprick &gt;proprioception. MMSE 26/29. WHO-DAS 18.75. Hb 12.6 g/dL, MCV 78.6, ESR 68, Rh F negative. Knee XRs normal. OGTT 8.4 mmol/L - 0 h., 10.1–2 h. Brain CT; Normal study. Retinal imaging, bilateral. Ebola retinal lesions and WWP</td>
<td>Migraine headache, asymmetric sensory peripheral neuropathy, major depressive disorder</td>
<td>MH follow up, Propranolol 20 mg daily, Gabapentin 300 mg noche, diet and diabetic clinic referral. Headache improved (unable to quantify), pain in feet improved. Review at 1 y: Decreased frequency of headaches, now occasional. Improvement in neuropathy</td>
</tr>
<tr>
<td>37 (F/12)</td>
<td>Fever, arthralgia/myalgia, intense fatigue, <strong>altered consciousness</strong>, seizures, abdominal pain, diarrhea, conjunctivitis, unconscious - 1 mo (15 d). C; value – 27.9</td>
<td>(454 d) Long period of coma post Ebola virus disease infection. Now deaf and blind with severe cognitive deficit requiring 24-h care. No focal weakness. Cerebrospinal fluid EBoV PCR negative. Brain CT – Significant marked parietal and temporal lobe atrophy</td>
<td>Severe neuro-cognitive impairment post viral encephalitis</td>
<td>Referral to orphanage for 24-h care</td>
</tr>
<tr>
<td>38 (M/21)</td>
<td>Fever, cough, sore throat, runny nose, chest pain, arthralgia/myalgia, intense fatigue, <strong>headache</strong>, shortness of breath, altered consciousness, abdominal pain, nausea, vomiting (21 d)</td>
<td>(503 d) All over headache with no associated symptoms. Visual hallucinations. Arthralgia</td>
<td>Undifferentiated headache, arthralgia</td>
<td>No data</td>
</tr>
</tbody>
</table>

*Boldface type indicates neurologic features.; MCA, middle cerebral artery; MH, mental health; WWP, white without pressure.*
**Technical Appendix Table 4.** Table showing demographic and clinical features of patients diagnosed with headache attending preliminary and specialist neurology and psychiatric clinics, n = 30*

<table>
<thead>
<tr>
<th>Pt. no.</th>
<th>Frequency and duration</th>
<th>Description/ location</th>
<th>Exacerbating and associated factors</th>
<th>History of headache</th>
<th>Other</th>
<th>Diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 (M/21)</td>
<td>Throbbing/ pounding. Frontal</td>
<td>Visual disturbance</td>
<td>No</td>
<td>ND</td>
<td>Common migraine</td>
<td></td>
</tr>
<tr>
<td>2 (M/47)</td>
<td>Every 2 weeks. Lasting up to 1 week</td>
<td>Intense. All over</td>
<td>Scotoma</td>
<td>No</td>
<td>Resolved by time of specialist review</td>
<td>Common migraine (resolved)</td>
</tr>
<tr>
<td>4 (M/33)</td>
<td>2 weekly. Lasting 1 d – 1 week</td>
<td>Band like</td>
<td>Scotoma, Confusion</td>
<td>No</td>
<td>ND</td>
<td>Common migraine</td>
</tr>
<tr>
<td>5 (F/54)</td>
<td>ND</td>
<td>All over</td>
<td>Scotoma, Mouth burning</td>
<td>No</td>
<td>ND</td>
<td>Undifferentiated headache</td>
</tr>
<tr>
<td>6 (F/18)</td>
<td>ND</td>
<td>All over</td>
<td>-</td>
<td>No</td>
<td>ND</td>
<td>Undifferentiated headache</td>
</tr>
<tr>
<td>7 (F/21)</td>
<td>Daily</td>
<td>Constant. Band-like</td>
<td>Difficulty sleeping</td>
<td>No</td>
<td>ND</td>
<td>Tension headache</td>
</tr>
<tr>
<td>8 (F/29)</td>
<td>ND</td>
<td>All over</td>
<td>None</td>
<td>No</td>
<td>ND</td>
<td>Undifferentiated headache</td>
</tr>
<tr>
<td>9 (F/26)</td>
<td>Daily (at night)</td>
<td>Frontal</td>
<td>Blurred vision</td>
<td>No</td>
<td>ND</td>
<td>Common migraine</td>
</tr>
<tr>
<td>11 (M/42)</td>
<td>ND</td>
<td>All over</td>
<td>Large left MCA stroke</td>
<td>No</td>
<td>ND</td>
<td>Undifferentiated headache</td>
</tr>
<tr>
<td>13 (F/58)</td>
<td>ND</td>
<td>All over</td>
<td>Eye pain, Altered vision</td>
<td>No</td>
<td>ND</td>
<td>Undifferentiated headache</td>
</tr>
<tr>
<td>14 (M/38)</td>
<td>Intermittent</td>
<td>All over</td>
<td>Photophobia, Eye pain, Fever</td>
<td>No</td>
<td>ND</td>
<td>Undifferentiated headache</td>
</tr>
<tr>
<td>15 (F/49)</td>
<td>2–3 times weekly</td>
<td>Band-like and constant</td>
<td>ND</td>
<td>No</td>
<td>ND</td>
<td>Problems with vision in left eye</td>
</tr>
<tr>
<td>16 (F/31)</td>
<td>Lasting a few hours</td>
<td>Aching. All over</td>
<td>Photophobia, Carrying loads, Dizziness</td>
<td>No</td>
<td>Onset 4/12 post d/c</td>
<td>Common Migraine</td>
</tr>
<tr>
<td>17 (F/51)</td>
<td>ND</td>
<td>All over</td>
<td>No</td>
<td>No</td>
<td>ND</td>
<td>Undifferentiated headache</td>
</tr>
<tr>
<td>19 (M/38)</td>
<td>ND</td>
<td>Pressure. All over</td>
<td>Thinking about loss of family Vertigo</td>
<td>ND</td>
<td>ND</td>
<td>Undifferentiated</td>
</tr>
<tr>
<td>20 (F/32)</td>
<td>ND</td>
<td>Right sided</td>
<td>Photophobia, Scotoma</td>
<td>No</td>
<td>Resolved by time of specialist review</td>
<td>Common migraine (resolved)</td>
</tr>
<tr>
<td>21 (F/32)</td>
<td>Monthly</td>
<td>Pounding. Frontal</td>
<td>Photophobia, Scotoma</td>
<td>No</td>
<td>No</td>
<td>Poor vision, Amenorrhea</td>
</tr>
<tr>
<td>22 (F/21)</td>
<td>Monthly</td>
<td>Lasting 5–7 d</td>
<td>Pounding, Vertex to occiput</td>
<td>Photophobia, Photophobia, Blurred vision, Dizziness</td>
<td>Maternal history</td>
<td>Started 5 weeks post EVD</td>
</tr>
<tr>
<td>23 (M/46)</td>
<td>ND</td>
<td>All over</td>
<td>Dizziness</td>
<td>No</td>
<td>ND</td>
<td>Undifferentiated headache</td>
</tr>
<tr>
<td>24 (F/43)</td>
<td>2–3x weekly</td>
<td>Aching. Frontal</td>
<td>Photophobia, Photophobia, Occ. vomiting</td>
<td>Yes. Previously mild, worse since EVD left eye</td>
<td>Intermediate uveitis</td>
<td>Common migraine</td>
</tr>
<tr>
<td>27 (M/25)</td>
<td>2–3x weekly</td>
<td>Pounding. Right sided</td>
<td>Photophobia, Blurred vision</td>
<td>No</td>
<td>ND</td>
<td>Common Migraine</td>
</tr>
<tr>
<td>28 (F/21)</td>
<td>Monthly</td>
<td>Pounding. Frontal</td>
<td>ND</td>
<td>No</td>
<td>Pregnant 24/42 weeks. Improving symptoms</td>
<td>Tension headache</td>
</tr>
<tr>
<td>29 (F/19)</td>
<td>Constant</td>
<td>Bank-like</td>
<td>Photophobia, Eye pain, Difficulty sleeping</td>
<td>No</td>
<td>ND</td>
<td>Undifferentiated headache</td>
</tr>
<tr>
<td>Pt no.</td>
<td>Frequency and duration</td>
<td>Description/ location</td>
<td>Exacerbating and associated factors</td>
<td>History of headache</td>
<td>Other</td>
<td>Diagnosis</td>
</tr>
<tr>
<td>--------</td>
<td>------------------------</td>
<td>-----------------------</td>
<td>-------------------------------------</td>
<td>---------------------</td>
<td>-------</td>
<td>-----------</td>
</tr>
<tr>
<td>30 (F/33)</td>
<td>Constant</td>
<td>Bilateral red eyes with pain</td>
<td>Intermittent fevers</td>
<td>ND</td>
<td>Anterior uveitis</td>
<td>Undifferentiated headache</td>
</tr>
<tr>
<td>31 (F/33)</td>
<td>Daily worse at night Up to 4 h</td>
<td>Pounding. Frontal Photophobia Photophobia Occ. Vomiting</td>
<td>5 y, worse since EVD</td>
<td>ND</td>
<td>ND</td>
<td>Common Migraine</td>
</tr>
<tr>
<td>32 (F/43)</td>
<td>Intermittent</td>
<td>All over</td>
<td>ND</td>
<td>No</td>
<td>Cloudy vision</td>
<td>Undifferentiated headache</td>
</tr>
<tr>
<td>33 (F/41)</td>
<td>Daily</td>
<td>Sharp becomes pounding. R sided Photophobia, Photophobia Blurred vision and vertigo</td>
<td>No</td>
<td>ND</td>
<td>ND</td>
<td>Common Migraine</td>
</tr>
<tr>
<td>34 (F/25)</td>
<td>ND</td>
<td>All over</td>
<td>Reduced acuity right eye</td>
<td>ND</td>
<td>ND</td>
<td>Undifferentiated headache</td>
</tr>
<tr>
<td>35 (M/35)</td>
<td>Monthly</td>
<td>Pounding. Left sided Photophobia Photophobia Difficulty sleeping</td>
<td>No</td>
<td>ND</td>
<td>ND</td>
<td>Common Migraine</td>
</tr>
<tr>
<td>38 (M/21)</td>
<td>ND</td>
<td>All over</td>
<td>ND</td>
<td>No</td>
<td>ND</td>
<td>Undifferentiated</td>
</tr>
</tbody>
</table>

*ND, no data.*
Technical Appendix Figure. Figure showing series of 3 histograms showing frequency of symptoms among patients attending the preliminary clinic (n=40) who had specific A) neurologic, B) ophthalmologic, and C) psychiatric symptoms. Error bars indicate 95% CI. ADL, activities of daily living.